,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,1900 Lake Park Drive,Suite 380,Smyrna,GA,30080,United States,(678) 384-7220,(678) 384-7281,https://www.geovax.com,Biotechnology,Healthcare,"GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.",14,"{'maxAge': 1, 'name': 'Mr. David Alan Dodd', 'age': 72, 'title': 'Chairman, Pres & CEO', 'yearBorn': 1950, 'fiscalYear': 2022, 'totalPay': 469015, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.539,0.54,0.5222,0.556,0.539,0.54,0.5222,0.556,0.0,2.935338,-0.66543204,100660,100660,352716,162700,162700,0.531,0.539,2200,3200,14253100,0.51,1.39,Infinity,0.56598,0.65543,0.0,0.0,USD,-3535784,0.0,26060481,26443600,794656,807616,1690761600,1693440000,0.0301,0.01239,0.060760003,2.4,0.0304,0.649,0.8305085,1672444800,1703980800,1688083200,-19317448,-0.78,-0.81,1:20,1600992000,0.179,NCM,EQUITY,GOVX,GOVX,"GeoVax Labs, Inc.","GeoVax Labs, Inc.",1601040600,America/New_York,EDT,-14400000,0.539,8.0,4.0,6.0,6.0,2.0,buy,4,17788912,0.673,-19741086,0,4.354,4.853,0,0.0,-0.45439,-0.85786,-11568527,-20663406,0.0,0.0,0.0,USD,
1,1900 Lake Park Drive,Suite 380,Smyrna,GA,30080,United States,(678) 384-7220,(678) 384-7281,https://www.geovax.com,Biotechnology,Healthcare,"GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.",14,"{'maxAge': 1, 'name': 'Mr. Mark W. Reynolds CPA, CPA', 'age': 60, 'title': 'CFO & Corp. Sec.', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 348200, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.539,0.54,0.5222,0.556,0.539,0.54,0.5222,0.556,0.0,2.935338,-0.66543204,100660,100660,352716,162700,162700,0.531,0.539,2200,3200,14253100,0.51,1.39,Infinity,0.56598,0.65543,0.0,0.0,USD,-3535784,0.0,26060481,26443600,794656,807616,1690761600,1693440000,0.0301,0.01239,0.060760003,2.4,0.0304,0.649,0.8305085,1672444800,1703980800,1688083200,-19317448,-0.78,-0.81,1:20,1600992000,0.179,NCM,EQUITY,GOVX,GOVX,"GeoVax Labs, Inc.","GeoVax Labs, Inc.",1601040600,America/New_York,EDT,-14400000,0.539,8.0,4.0,6.0,6.0,2.0,buy,4,17788912,0.673,-19741086,0,4.354,4.853,0,0.0,-0.45439,-0.85786,-11568527,-20663406,0.0,0.0,0.0,USD,
2,1900 Lake Park Drive,Suite 380,Smyrna,GA,30080,United States,(678) 384-7220,(678) 384-7281,https://www.geovax.com,Biotechnology,Healthcare,"GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.",14,"{'maxAge': 1, 'name': 'Dr. Mark J. Newman Ph.D.', 'age': 67, 'title': 'Chief Scientific Officer', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 364166, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.539,0.54,0.5222,0.556,0.539,0.54,0.5222,0.556,0.0,2.935338,-0.66543204,100660,100660,352716,162700,162700,0.531,0.539,2200,3200,14253100,0.51,1.39,Infinity,0.56598,0.65543,0.0,0.0,USD,-3535784,0.0,26060481,26443600,794656,807616,1690761600,1693440000,0.0301,0.01239,0.060760003,2.4,0.0304,0.649,0.8305085,1672444800,1703980800,1688083200,-19317448,-0.78,-0.81,1:20,1600992000,0.179,NCM,EQUITY,GOVX,GOVX,"GeoVax Labs, Inc.","GeoVax Labs, Inc.",1601040600,America/New_York,EDT,-14400000,0.539,8.0,4.0,6.0,6.0,2.0,buy,4,17788912,0.673,-19741086,0,4.354,4.853,0,0.0,-0.45439,-0.85786,-11568527,-20663406,0.0,0.0,0.0,USD,
3,1900 Lake Park Drive,Suite 380,Smyrna,GA,30080,United States,(678) 384-7220,(678) 384-7281,https://www.geovax.com,Biotechnology,Healthcare,"GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.",14,"{'maxAge': 1, 'name': 'Dr. Harriet Latham Robinson Ph.D.', 'age': 84, 'title': 'Founder & Member of Scientific Advisory Board', 'yearBorn': 1938, 'fiscalYear': 2020, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.539,0.54,0.5222,0.556,0.539,0.54,0.5222,0.556,0.0,2.935338,-0.66543204,100660,100660,352716,162700,162700,0.531,0.539,2200,3200,14253100,0.51,1.39,Infinity,0.56598,0.65543,0.0,0.0,USD,-3535784,0.0,26060481,26443600,794656,807616,1690761600,1693440000,0.0301,0.01239,0.060760003,2.4,0.0304,0.649,0.8305085,1672444800,1703980800,1688083200,-19317448,-0.78,-0.81,1:20,1600992000,0.179,NCM,EQUITY,GOVX,GOVX,"GeoVax Labs, Inc.","GeoVax Labs, Inc.",1601040600,America/New_York,EDT,-14400000,0.539,8.0,4.0,6.0,6.0,2.0,buy,4,17788912,0.673,-19741086,0,4.354,4.853,0,0.0,-0.45439,-0.85786,-11568527,-20663406,0.0,0.0,0.0,USD,
4,1900 Lake Park Drive,Suite 380,Smyrna,GA,30080,United States,(678) 384-7220,(678) 384-7281,https://www.geovax.com,Biotechnology,Healthcare,"GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.",14,"{'maxAge': 1, 'name': 'Dr. Kelly T. McKee Jr., M.D., M.P.H.', 'age': 72, 'title': 'Chief Medical Officer', 'yearBorn': 1950, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.539,0.54,0.5222,0.556,0.539,0.54,0.5222,0.556,0.0,2.935338,-0.66543204,100660,100660,352716,162700,162700,0.531,0.539,2200,3200,14253100,0.51,1.39,Infinity,0.56598,0.65543,0.0,0.0,USD,-3535784,0.0,26060481,26443600,794656,807616,1690761600,1693440000,0.0301,0.01239,0.060760003,2.4,0.0304,0.649,0.8305085,1672444800,1703980800,1688083200,-19317448,-0.78,-0.81,1:20,1600992000,0.179,NCM,EQUITY,GOVX,GOVX,"GeoVax Labs, Inc.","GeoVax Labs, Inc.",1601040600,America/New_York,EDT,-14400000,0.539,8.0,4.0,6.0,6.0,2.0,buy,4,17788912,0.673,-19741086,0,4.354,4.853,0,0.0,-0.45439,-0.85786,-11568527,-20663406,0.0,0.0,0.0,USD,
5,1900 Lake Park Drive,Suite 380,Smyrna,GA,30080,United States,(678) 384-7220,(678) 384-7281,https://www.geovax.com,Biotechnology,Healthcare,"GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.",14,"{'maxAge': 1, 'name': 'Jeffrey  Welch', 'title': 'Head of Process Devel. & Manufacturing Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.539,0.54,0.5222,0.556,0.539,0.54,0.5222,0.556,0.0,2.935338,-0.66543204,100660,100660,352716,162700,162700,0.531,0.539,2200,3200,14253100,0.51,1.39,Infinity,0.56598,0.65543,0.0,0.0,USD,-3535784,0.0,26060481,26443600,794656,807616,1690761600,1693440000,0.0301,0.01239,0.060760003,2.4,0.0304,0.649,0.8305085,1672444800,1703980800,1688083200,-19317448,-0.78,-0.81,1:20,1600992000,0.179,NCM,EQUITY,GOVX,GOVX,"GeoVax Labs, Inc.","GeoVax Labs, Inc.",1601040600,America/New_York,EDT,-14400000,0.539,8.0,4.0,6.0,6.0,2.0,buy,4,17788912,0.673,-19741086,0,4.354,4.853,0,0.0,-0.45439,-0.85786,-11568527,-20663406,0.0,0.0,0.0,USD,
6,1900 Lake Park Drive,Suite 380,Smyrna,GA,30080,United States,(678) 384-7220,(678) 384-7281,https://www.geovax.com,Biotechnology,Healthcare,"GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.",14,"{'maxAge': 1, 'name': 'Dr. John W. Sharkey Ph.D.', 'age': 66, 'title': 'VP of Bus. Devel.', 'yearBorn': 1956, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.539,0.54,0.5222,0.556,0.539,0.54,0.5222,0.556,0.0,2.935338,-0.66543204,100660,100660,352716,162700,162700,0.531,0.539,2200,3200,14253100,0.51,1.39,Infinity,0.56598,0.65543,0.0,0.0,USD,-3535784,0.0,26060481,26443600,794656,807616,1690761600,1693440000,0.0301,0.01239,0.060760003,2.4,0.0304,0.649,0.8305085,1672444800,1703980800,1688083200,-19317448,-0.78,-0.81,1:20,1600992000,0.179,NCM,EQUITY,GOVX,GOVX,"GeoVax Labs, Inc.","GeoVax Labs, Inc.",1601040600,America/New_York,EDT,-14400000,0.539,8.0,4.0,6.0,6.0,2.0,buy,4,17788912,0.673,-19741086,0,4.354,4.853,0,0.0,-0.45439,-0.85786,-11568527,-20663406,0.0,0.0,0.0,USD,
